NACDS president Hannan
This article was originally published in The Tan Sheet
Executive Summary
Robert Hannan has been named interim president & CEO of the National Association of Chain Drug Stores, effective April 3, the organization announces March 31. Hannan, a veteran in the chain drug industry with over 40 years experience, has served as president of Thrift Drug and vice chairman of Eckerd Drug after its acquisition of the Thrift Drug chain, according to NACDS. Having since retired from the industry, he currently runs his own consulting firm, Hannan Executive Services, Inc. The exec previously served as interim NACDS president in 1999. Hannan replaces Craig Fuller, who resigned as president & CEO March 20 (1"The Tan Sheet" March 27, 2006, In Brief). Exec VP & COO Bill Sittmann, who served in the White House with Fuller under Bush and Reagan, also resigned from NACDS March 31...
You may also be interested in...
Fuller departure
NACDS President & CEO Craig Fuller is resigning as of April 7, the exec confirms in his weekly newsletter March 20. "When it comes time to explore new directions and new leadership, presidents and boards are supposed to send a signal that it is time for a change. That signal has been sent in a remarkably professional and constructive manner," Fuller says. The chain drug store association indicated March 14 that its board had met with Fuller, who had offered his resignation (1"The Tan Sheet" March 20, 2006 , In Brief)...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.